Drug Trial Radar · NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- Auricula Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Simbec-Orion Group
- First posted
- Aug 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
Conditions
- Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
- Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
- Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
- Advanced Solid Tumors
- Advanced or Metastatic KRAS-mutant Tumor
Interventions
WEF-001Drug
Starting dose of 0.3 mg/m2 q4wks IV, dose escalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: To characterize the safety and tolerability profiles of WEF-001 administered as monotherapy.Time frame: Through study completion, an average of 1 year.
- Phase 2: To evaluate the antitumour activity following WEF-001 administration as monotherapy.Time frame: Trough study completion, an average of 2 years.
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
NEXT Oncology Dallas
Dallas, Texas · Recruiting
Next Oncology, San Antonio
San Antonio, Texas · Recruiting
Princess Margareth Cancer Center
Toronto, Ontario, Canada · Recruiting
Oxford University Hospital
Headington, Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.